Broadening the PARP playing field
How the PARP field is mapping out new synthetic lethality plays
With its latest clinical win for Lynparza, AstraZeneca is leading the field in stretching the use of PARP inhibitors beyond tumors that carry BRCA mutations. The results highlight one piece of a broader strategy companies are taking to leverage synthetic lethality to extend the reach of the first generation of PARP inhibitors.
On Feb. 26, AstraZeneca plc and partner Merck & Co. Inc. announced that Lynparza olaparib met the primary endpoint in the Phase III POLO trial as maintenance therapy in first-line metastatic pancreatic cancer patients who harbor germline BRCA (gBRCA) mutations. ...